Schering-Plough 4Q Revenues: $2.3 billion (+6%) 4Q Earnings: $126 million (loss of $834 million 4Q2004) FY Revenues: $9.5 billion (+15%) FY Earnings: $269 million (loss of $947 million FY2004) Comments: Sales increase for 4Q was driven by the growth of prescription pharmaceuticals, led by Peg-Intron, Rebetol, Nasonex and Remicade. Peg-Intron sales were $214 million, up 55%. Rebetol sales were $94 million, up 93%. Nasonex sales were $185 million, up 27%. Remicade sales were $2...